Join
Live feed
·
PRReleasevia Quantisnow
Pyxis Oncology Inc. logo

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

ByQuantisnow·Wall Street's wire, on your screen.
PYXS· Pyxis Oncology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PYXS (Pyxis Oncology Inc.) and more on Quantisnow.